Pull to refresh
Logo
CVS settles federal opioid prescribing case for $315M

CVS settles federal opioid prescribing case for $315M

Rule Changes

Justice Department ends 12-year dispensing case; CVS adopts new oversight measures without admitting wrongdoing

Yesterday: CVS confirms settlement and compliance terms

Overview

Updated 1 hour ago

CVS Pharmacy agreed to pay $315 million to settle federal allegations that it illegally filled opioid prescriptions for more than a decade from 2013 through 2025, then billed Medicare for many of those invalid claims. The company admitted no wrongdoing.

The settlement resolves a lawsuit the Justice Department filed in December 2024, accusing CVS of filling prescriptions from "pill mill" prescribers and dangerous "trinity" combinations of opioids with other addictive drugs. Under a separate agreement with the Drug Enforcement Administration, CVS must now set up a reporting hotline, monitor pharmacy dispensing patterns, and screen prescribers suspected of illegal prescribing.

Why it matters

The deal forces one of America's largest pharmacy chains to install opioid monitoring systems, a new compliance standard for every pharmacy filling controlled substances.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$315M
Federal settlement amount
CVS pays to resolve DOJ opioid prescribing and False Claims Act allegations.
$5B
2022 state and tribal settlement
CVS's earlier, larger opioid settlement with states, localities, and tribes.
12 years
Years of alleged violations
DOJ alleged unlawful dispensing from October 2013 through December 2025.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

October 2013 October 2026

5 events Latest: Yesterday
Tap a bar to jump to that date
  1. CVS confirms settlement and compliance terms

    Latest Settlement

    CVS confirms the $315 million settlement including DEA oversight agreement.

  2. DOJ announces $315M settlement

    Settlement

    CVS agrees to pay $315 million; admits no wrongdoing.

  3. CVS pays $5B to states and tribes

    Settlement

    CVS agrees to nearly $5 billion settlement with state, local, and tribal governments.

Scenarios

1

CVS completes compliance overhaul without further federal action

Likely Resolves by Oct 13, 2027

Discussed by: Healthcare Dive, TIKR.com analysts

CVS implements the DEA memorandum of agreement: hotline, dispensing monitoring, prescriber screening. TIKR analysts note the settlement is under 3% of CVS's operating cash flow, suggesting minimal financial strain. If compliance holds and no new violations surface, the federal case closes.

2

Whistleblower award set in CVS settlement

Likely Resolves by Oct 13, 2028

Discussed by: Bloomberg Law, court observers

Hillary Estright, the former CVS employee who filed the 2022 qui tam lawsuit, is entitled to a share of the $315 million recovery under the False Claims Act. The court determines her award, typically 15-25% of the recovery in intervened cases.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

August 2026

Walmart DOJ Opioid Settlement (August 2026)

Walmart agreed to pay $50 million to resolve a similar DOJ lawsuit over opioid dispensing, far less than CVS's $315 million settlement. The difference in scale reflects the specific allegations and company size.

Then

Walmart avoided prolonged litigation and further reputational damage.

Now

The settlement reinforced the DOJ's pattern of pursuing pharmacy chains for opioid dispensing.

Why this matters now

Shows the range of federal opioid settlements, with CVS at the higher end.

2022

CVS State and Tribal Settlement (2022)

CVS agreed to pay nearly $5 billion to settle thousands of claims by states, localities, and Native American tribes over its role in the opioid epidemic. That settlement covered dispensing and distribution practices.

Then

CVS resolved a wave of civil claims without admitting wrongdoing.

Now

The 2022 settlement didn't preclude federal action, demonstrated by the 2026 DOJ resolution.

Why this matters now

The federal settlement adds to CVS's total opioid liabilities, which exceed $5 billion across all cases.

September 2019

Purdue Pharma Bankruptcy (September 2019)

OxyContin maker Purdue Pharma filed for Chapter 11 bankruptcy amid thousands of lawsuits from states, cities, and individuals over its role in the opioid crisis. The company faced billions in potential liability.

Then

Bankruptcy paused litigation while Purdue negotiated a settlement plan.

Now

The case established that opioid manufacturers and distributors face massive liability, setting a precedent for pharmacy chains like CVS.

Why this matters now

Illustrates the accountability wave that eventually reached pharmacies directly involved in dispensing.

Sources

(8)